Table 1.

GBM patient demographic variables

Age (y)GenderICRAlivePost-vac RxTTSIFN-γ
59MNoNoCPT-11132NA
56MNoNo335NA
57FNoNo1380.46
28FNoNoCPL/AC, TMX, CCNU4090.34
55MYesNoGliadel5120.48
54MYesNo5520.5
24MYesNoTMZ, CCNU, CPT-116690.54
53MYesNoTMZ, PCV1930.6
50MYesNoTMZ, VP16, THL, CBRX4480.64
60FNoNoTMZ, GLV3350.8
22MYesYesIRESSA/RAPA12160.85
42MNoNoTMZ5200.81
58MYesNo7280.85
53MYesNoTMZ, PCV3750.97
47MYesNo1891.2
58MNoNo4141.38
74MYesNo2351.49
66MYesNoTMZ4231.66
63MYesNoTMZ, GLV, CIV4641.67
37MYesNo2271.73
42MYesNoTMZ3302.02
39MYesNoTMZ, AC6622.1
59FYesNo4552.23
55MYesNoTMZ3414.31
64MYesNoTMZ9424.6
65FYesYesIRESSA/RAPA9945.2
44FYesYes9105.3
52MNoNoTMZ7775.95
67FYesNoTMZ, CCNU7847.1
68FYesNo4389.85
40MYesNoTMZ, GEF/RAPA64313.45
44MYesYesTRCVA114817.1
61FNoNo66450
48FYesYesTMZ119251.32
  • Abbreviations: M, male; F, female; ICR, image-complete surgical resection before vaccination; TTS, immediate postvaccine TTS from prevaccine surgery; IFN-γ, post–third vaccine enhancement of IFN-γ production (italicized value is post–second vaccine from a patient who expired before the third vaccine); CPL, carboplatin; AC, accutaner; TMX, tamoxifen; TMZ, temozolamide; THL, thalidomide; CBRX, Celebrexr; GLV, Gleevecr; RAPA, rapamycin; CIV, continuous infusion of vincristine; GEF, gefitinib; TRCVA, Tarcevar (erlotinib).